Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.

Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):71-7. doi: 10.1016/j.pnpbp.2011.08.010. Epub 2011 Aug 22.

PMID:
21878360
2.

Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.

Gil-ad I, Shtaif B, Shiloh R, Weizman A.

Cell Mol Neurobiol. 2001 Dec;21(6):705-16.

PMID:
12043843
3.
4.

Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.

Yang MC, Lung FW.

Psychopharmacology (Berl). 2011 Oct;217(3):397-410. doi: 10.1007/s00213-011-2291-7. Epub 2011 Apr 27.

PMID:
21523348
5.

Paliperidone protects SK-N-SH cells against glutamate toxicity via Akt1/GSK3β signaling pathway.

Peng L, Zhang X, Cui X, Zhu D, Wu J, Sun D, Yue Q, Li Z, Liu H, Li G, Zhang J, Xu H, Liu F, Qin C, Li M, Sun J.

Schizophr Res. 2014 Aug;157(1-3):120-7. doi: 10.1016/j.schres.2014.05.037. Epub 2014 Jun 22.

PMID:
24962437
6.

Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):236-7.

PMID:
18092400
7.

Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.

Awouters FH, Lewi PJ.

Arzneimittelforschung. 2007;57(10):625-32. Review.

PMID:
18074755
8.

Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol.

Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T.

J Neural Transm (Vienna). 2004 Jun;111(6):667-81. Epub 2004 Apr 2.

PMID:
15168214
9.

A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

Marchese G, Pittau B, Casu G, Peddio G, Spada GP, Pira M, Deriu A, Portesani F, Pisu C, Lazzari P, Pani L.

Eur Psychiatry. 2010 Mar;25(2):92-100. doi: 10.1016/j.eurpsy.2009.05.008. Epub 2009 Jul 28.

PMID:
19640686
10.

Paliperidone for schizophrenia.

Dolder C, Nelson M, Deyo Z.

Am J Health Syst Pharm. 2008 Mar 1;65(5):403-13. doi: 10.2146/ajhp070261. Review.

PMID:
18281731
11.

Paliperidone: quo vadis?

Citrome L.

Int J Clin Pract. 2007 Apr;61(4):653-62. Epub 2007 Mar 2. Review.

PMID:
17343660
12.

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia..

J Clin Psychiatry. 2007 Nov;68(11):1763-74.

PMID:
18052570
13.

Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.

Sun F, Su Z, Sui C, Zhang C, Yuan L, Meng Q, Teng L, Li Y.

Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):656-62. doi: 10.1111/j.1742-7843.2010.00552.x.

14.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
15.

First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.

Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M.

Psychiatr Danub. 2011 Dec;23(4):384-8.

16.

Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells.

Kim NR, Park SW, Lee JG, Kim YH.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):633-42. Epub 2007 Nov 12.

PMID:
18055082
17.

Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress.

Mas S, Gassó P, Trias G, Bernardo M, Lafuente A.

Fundam Clin Pharmacol. 2012 Dec;26(6):712-21. doi: 10.1111/j.1472-8206.2011.00988.x. Epub 2011 Sep 19.

PMID:
21923690
18.

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM.

Int Clin Psychopharmacol. 2008 Jul;23(4):209-15. doi: 10.1097/YIC.0b013e3282fce651.

PMID:
18545059
19.

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

Pani L, Marchese G.

Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. doi: 10.1517/17425240902780158. Review.

PMID:
19317589
20.

Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.

Dremencov E, El Mansari M, Blier P.

Psychopharmacology (Berl). 2007 Sep;194(1):63-72. Epub 2007 May 27.

PMID:
17530476

Supplemental Content

Support Center